Applied Therapeutics Past Earnings Performance
Past criteria checks 0/6
Applied Therapeutics's earnings have been declining at an average annual rate of -20.1%, while the Biotechs industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 67.3% per year.
Key information
-20.1%
Earnings growth rate
17.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 67.3% |
| Return on equity | -222.5% |
| Net Margin | 48,375.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Applied Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -161 | 29 | 0 |
| 31 Mar 24 | 0 | -194 | 24 | 0 |
| 31 Dec 23 | 10 | -120 | 21 | 0 |
| 30 Sep 23 | 11 | -97 | 22 | -33 |
| 30 Jun 23 | 11 | -73 | 24 | -30 |
| 31 Mar 23 | 11 | -70 | 25 | -15 |
| 31 Dec 22 | 0 | -83 | 27 | 0 |
| 30 Sep 22 | 0 | -95 | 32 | 59 |
| 30 Jun 22 | 0 | -105 | 36 | 64 |
| 31 Mar 22 | 0 | -105 | 41 | 63 |
| 31 Dec 21 | 0 | -106 | 43 | 63 |
| 30 Sep 21 | 0 | -102 | 42 | 61 |
| 30 Jun 21 | 0 | -104 | 41 | 63 |
| 31 Mar 21 | 0 | -106 | 37 | 69 |
| 31 Dec 20 | 0 | -94 | 33 | 62 |
| 30 Sep 20 | 0 | -88 | 27 | 62 |
| 30 Jun 20 | 0 | -69 | 21 | 49 |
| 31 Mar 20 | 0 | -49 | 17 | 33 |
| 31 Dec 19 | 0 | -46 | 13 | 32 |
| 30 Sep 19 | 0 | -35 | 10 | 24 |
| 30 Jun 19 | 0 | -28 | 7 | 19 |
| 31 Mar 19 | 0 | -23 | 3 | 17 |
| 31 Dec 18 | 0 | -17 | 2 | 11 |
Quality Earnings: 2UV is currently unprofitable.
Growing Profit Margin: 2UV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2UV is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare 2UV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2UV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 2UV has a negative Return on Equity (-222.52%), as it is currently unprofitable.